ES2951874T3 - Antagonistas del receptor de vasopresina y productos y métodos relacionados con los mismos - Google Patents

Info

Publication number

ES2951874T3

ES2951874T3 ES18779495T ES18779495T ES2951874T3 ES 2951874 T3 ES2951874 T3 ES 2951874T3 ES 18779495 T ES18779495 T ES 18779495T ES 18779495 T ES18779495 T ES 18779495T ES 2951874 T3 ES2951874 T3 ES 2951874T3

Authority

ES

Spain

Prior art keywords

independently

alkyl

formula

halo

haloalkyl

Prior art date

2017-09-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 66
• 239000002536 vasopressin receptor antagonist Substances 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 claims abstract description 495
• 150000003839 salts Chemical class 0.000 claims abstract description 265
• 239000012453 solvate Substances 0.000 claims abstract description 251
• 125000000217 alkyl group Chemical group 0.000 claims description 916
• 125000003545 alkoxy group Chemical group 0.000 claims description 756
• 125000005843 halogen group Chemical group 0.000 claims description 597
• 125000001188 haloalkyl group Chemical group 0.000 claims description 462
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 412
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 192
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 187
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 183
• 239000000203 mixture Substances 0.000 claims description 119
• 125000003118 aryl group Chemical group 0.000 claims description 97
• 125000001072 heteroaryl group Chemical group 0.000 claims description 89
• 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 84
• KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 74
• 125000000623 heterocyclic group Chemical group 0.000 claims description 74
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 73
• -1 methoxy, ethoxy, isopropoxy Chemical group 0.000 claims description 57
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
• 208000035475 disorder Diseases 0.000 claims description 46
• 108010004977 Vasopressins Proteins 0.000 claims description 44
• GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 43
• 102000002852 Vasopressins Human genes 0.000 claims description 43
• 229960003726 vasopressin Drugs 0.000 claims description 43
• 208000019901 Anxiety disease Diseases 0.000 claims description 25
• 208000019022 Mood disease Diseases 0.000 claims description 21
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 208000029560 autism spectrum disease Diseases 0.000 claims description 16
• 208000024714 major depressive disease Diseases 0.000 claims description 16
• 230000009286 beneficial effect Effects 0.000 claims description 15
• 230000016571 aggressive behavior Effects 0.000 claims description 14
• 230000001419 dependent effect Effects 0.000 claims description 14
• 208000019906 panic disease Diseases 0.000 claims description 12
• 230000027288 circadian rhythm Effects 0.000 claims description 11
• 208000020401 Depressive disease Diseases 0.000 claims description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
• 201000000980 schizophrenia Diseases 0.000 claims description 10
• 239000003085 diluting agent Substances 0.000 claims description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
• 230000028327 secretion Effects 0.000 claims description 9
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 8
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
• 208000019116 sleep disease Diseases 0.000 claims description 8
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
• 208000020016 psychiatric disease Diseases 0.000 claims description 7
• 230000001225 therapeutic effect Effects 0.000 claims description 7
• 206010001488 Aggression Diseases 0.000 claims description 6
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 6
• 206010013935 Dysmenorrhoea Diseases 0.000 claims description 6
• 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 6
• 206010034912 Phobia Diseases 0.000 claims description 6
• 208000028017 Psychotic disease Diseases 0.000 claims description 6
• 206010041250 Social phobia Diseases 0.000 claims description 6
• 230000003042 antagnostic effect Effects 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 229910052731 fluorine Inorganic materials 0.000 claims description 6
• 229910052736 halogen Inorganic materials 0.000 claims description 6
• 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 6
• 230000003557 neuropsychological effect Effects 0.000 claims description 6
• 208000019899 phobic disease Diseases 0.000 claims description 6
• 208000007415 Anhedonia Diseases 0.000 claims description 5
• 208000020925 Bipolar disease Diseases 0.000 claims description 5
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
• 208000012761 aggressive behavior Diseases 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 239000003814 drug Substances 0.000 claims description 5
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
• 238000000338 in vitro Methods 0.000 claims description 5
• 208000017194 Affective disease Diseases 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• 239000001257 hydrogen Substances 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 238000001228 spectrum Methods 0.000 claims description 4
• 206010057671 Female sexual dysfunction Diseases 0.000 claims description 3
• 206010057672 Male sexual dysfunction Diseases 0.000 claims description 3
• 208000026139 Memory disease Diseases 0.000 claims description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
• 208000024732 dysthymic disease Diseases 0.000 claims description 3
• 208000015046 intermittent explosive disease Diseases 0.000 claims description 3
• 238000011321 prophylaxis Methods 0.000 claims description 3
• 208000000810 Separation Anxiety Diseases 0.000 claims description 2
• 208000013200 Stress disease Diseases 0.000 claims description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
• 208000000509 infertility Diseases 0.000 claims description 2
• 230000036512 infertility Effects 0.000 claims description 2
• 231100000535 infertility Toxicity 0.000 claims description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
• 208000022610 schizoaffective disease Diseases 0.000 claims description 2
• 208000025874 separation anxiety disease Diseases 0.000 claims description 2
• 150000002431 hydrogen Chemical group 0.000 claims 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
• 208000020685 sleep-wake disease Diseases 0.000 claims 1
• 102000005962 receptors Human genes 0.000 abstract description 44
• 108020003175 receptors Proteins 0.000 abstract description 44
• 238000003786 synthesis reaction Methods 0.000 abstract description 33
• 230000015572 biosynthetic process Effects 0.000 abstract description 31
• 102000004136 Vasopressin Receptors Human genes 0.000 abstract description 12
• 108090000643 Vasopressin Receptors Proteins 0.000 abstract description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 59
• 239000000243 solution Substances 0.000 description 57
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 43
• 238000005160 1H NMR spectroscopy Methods 0.000 description 42
• 210000004027 cell Anatomy 0.000 description 41
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 37
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
• 101800001144 Arg-vasopressin Proteins 0.000 description 29
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 29
• 239000007787 solid Substances 0.000 description 28
• 238000011282 treatment Methods 0.000 description 27
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
• 238000006243 chemical reaction Methods 0.000 description 21
• AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 20
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
• 238000002953 preparative HPLC Methods 0.000 description 20
• 239000003643 water by type Substances 0.000 description 20
• 230000000694 effects Effects 0.000 description 19
• 239000000543 intermediate Substances 0.000 description 19
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 238000007792 addition Methods 0.000 description 18
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
• 238000003556 assay Methods 0.000 description 17
• 208000024891 symptom Diseases 0.000 description 17
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
• 238000003818 flash chromatography Methods 0.000 description 16
• 239000008194 pharmaceutical composition Substances 0.000 description 16
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
• 230000035882 stress Effects 0.000 description 16
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
• 239000012131 assay buffer Substances 0.000 description 15
• 239000003921 oil Substances 0.000 description 15
• 235000019198 oils Nutrition 0.000 description 15
• 239000002904 solvent Substances 0.000 description 14
• 229910052799 carbon Inorganic materials 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
• 235000019439 ethyl acetate Nutrition 0.000 description 12
• 239000012074 organic phase Substances 0.000 description 12
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 12
• 230000033228 biological regulation Effects 0.000 description 11
• 239000000284 extract Substances 0.000 description 11
• 239000001963 growth medium Substances 0.000 description 11
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• 239000008279 sol Substances 0.000 description 11
• 230000036506 anxiety Effects 0.000 description 10
• 239000010410 layer Substances 0.000 description 10
• 229910052757 nitrogen Inorganic materials 0.000 description 10
• 235000017557 sodium bicarbonate Nutrition 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 230000002265 prevention Effects 0.000 description 9
• 230000008485 antagonism Effects 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 239000011575 calcium Chemical class 0.000 description 8
• 239000000975 dye Substances 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 238000004808 supercritical fluid chromatography Methods 0.000 description 8
• 206010033664 Panic attack Diseases 0.000 description 7
• 230000006399 behavior Effects 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 230000002526 effect on cardiovascular system Effects 0.000 description 7
• 125000005842 heteroatom Chemical group 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000002464 receptor antagonist Substances 0.000 description 7
• 229940044551 receptor antagonist Drugs 0.000 description 7
• 239000000377 silicon dioxide Substances 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 235000019341 magnesium sulphate Nutrition 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 229910052708 sodium Inorganic materials 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 208000011580 syndromic disease Diseases 0.000 description 6
• 230000001960 triggered effect Effects 0.000 description 6
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
• 206010003805 Autism Diseases 0.000 description 5
• 208000020706 Autistic disease Diseases 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
• 206010010219 Compulsions Diseases 0.000 description 5
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
• 229910000024 caesium carbonate Inorganic materials 0.000 description 5
• 229910052791 calcium Inorganic materials 0.000 description 5
• 125000004432 carbon atom Chemical group C* 0.000 description 5
• 230000037326 chronic stress Effects 0.000 description 5
• 230000002060 circadian Effects 0.000 description 5
• 238000004891 communication Methods 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000007958 sleep Effects 0.000 description 5
• 230000003997 social interaction Effects 0.000 description 5
• 208000011117 substance-related disease Diseases 0.000 description 5
• APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 206010029897 Obsessive thoughts Diseases 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
• 230000036772 blood pressure Effects 0.000 description 4
• 239000012267 brine Substances 0.000 description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
• 239000013058 crude material Substances 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 239000003607 modifier Substances 0.000 description 4
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 150000007524 organic acids Chemical class 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 229960005235 piperonyl butoxide Drugs 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 208000012672 seasonal affective disease Diseases 0.000 description 4
• 230000011273 social behavior Effects 0.000 description 4
• 239000012279 sodium borohydride Substances 0.000 description 4
• 229910000033 sodium borohydride Inorganic materials 0.000 description 4
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• 210000004291 uterus Anatomy 0.000 description 4
• QDXQAOGNBCOEQX-UHFFFAOYSA-N 1-methylcyclohexa-1,4-diene Chemical compound CC1=CCC=CC1 QDXQAOGNBCOEQX-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• UHWBUYHUQSOCGV-UHFFFAOYSA-N 6-chloro-1-[6-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptane-2-carbonyl]-2,3-dihydroquinolin-4-one Chemical compound ClC=1C=C2C(CCN(C2=CC=1)C(=O)N1CC2(C1)CN(C2)C1=NC=C(C=C1)F)=O UHWBUYHUQSOCGV-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 102400000739 Corticotropin Human genes 0.000 description 3
• 101800000414 Corticotropin Proteins 0.000 description 3
• 208000037487 Endotoxemia Diseases 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 239000012981 Hank's balanced salt solution Substances 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
• 239000001099 ammonium carbonate Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000003542 behavioural effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000000748 cardiovascular system Anatomy 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 210000001268 chyle Anatomy 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 208000010877 cognitive disease Diseases 0.000 description 3
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
• 229960000258 corticotropin Drugs 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 239000003797 essential amino acid Substances 0.000 description 3
• 235000020776 essential amino acid Nutrition 0.000 description 3
• LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 230000037406 food intake Effects 0.000 description 3
• 235000012631 food intake Nutrition 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 239000012216 imaging agent Substances 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 230000013016 learning Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000002595 magnetic resonance imaging Methods 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 230000036651 mood Effects 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 230000036407 pain Effects 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 239000000700 radioactive tracer Substances 0.000 description 3
• 230000003252 repetitive effect Effects 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• NJXZWIIMWNEOGJ-WEWKHQNJSA-N (2s,4r)-1-[(3r)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-n,n-dimethylpyrrolidine-2-carboxamide Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2[C@@](N2[C@@H](C[C@@H](O)C2)C(=O)N(C)C)(C=2C(=CC=CC=2)OC)C1=O NJXZWIIMWNEOGJ-WEWKHQNJSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• GMTRQFVALRGTAZ-UHFFFAOYSA-N 2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptane Chemical compound FC=1C=CC(=NC=1)N1CC2(C1)CNC2 GMTRQFVALRGTAZ-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• FAJYAMFPPKLZNG-UHFFFAOYSA-N 7-chloro-3-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound ClC1=CC=C2NC(C)COC2=C1 FAJYAMFPPKLZNG-UHFFFAOYSA-N 0.000 description 2
• 102400000345 Angiotensin-2 Human genes 0.000 description 2
• 101800000733 Angiotensin-2 Proteins 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
• 208000011597 CGF1 Diseases 0.000 description 2
• OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 2
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 101150065749 Churc1 gene Proteins 0.000 description 2
• 208000034608 Congenital tufting enteropathy Diseases 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000027534 Emotional disease Diseases 0.000 description 2
• 206010049119 Emotional distress Diseases 0.000 description 2
• CSPCLZSTBCUBSZ-UHFFFAOYSA-N FC1=CC(=C(C=C1F)NC(CO)C)I Chemical compound FC1=CC(=C(C=C1F)NC(CO)C)I CSPCLZSTBCUBSZ-UHFFFAOYSA-N 0.000 description 2
• 108700012941 GNRH1 Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• 101000954157 Homo sapiens Vasopressin V1a receptor Proteins 0.000 description 2
• 101000954141 Homo sapiens Vasopressin V1b receptor Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 206010062767 Hypophysitis Diseases 0.000 description 2
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 208000030990 Impulse-control disease Diseases 0.000 description 2
• 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• 229910052779 Neodymium Inorganic materials 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 208000005392 Spasm Diseases 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 229940116211 Vasopressin antagonist Drugs 0.000 description 2
• 206010047163 Vasospasm Diseases 0.000 description 2
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 201000005255 adrenal gland hyperfunction Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229950006323 angiotensin ii Drugs 0.000 description 2
• 230000002686 anti-diuretic effect Effects 0.000 description 2
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 230000005587 bubbling Effects 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 239000013553 cell monolayer Substances 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 2
• 238000003271 compound fluorescence assay Methods 0.000 description 2
• 201000001416 congenital diarrhea 5 with tufting enteropathy Diseases 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• 125000005879 dioxolanyl group Chemical group 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 230000009429 distress Effects 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• VZGWSAVADNSYRB-LURJTMIESA-N ethyl (2S)-2-(4,5-difluoro-2-iodoanilino)propanoate Chemical compound FC1=CC(=C(C=C1F)N[C@@H](C)C(=O)OCC)I VZGWSAVADNSYRB-LURJTMIESA-N 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 230000023597 hemostasis Effects 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000002197 limbic effect Effects 0.000 description 2
• 210000003715 limbic system Anatomy 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 229950004002 nelivaptan Drugs 0.000 description 2
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 210000003635 pituitary gland Anatomy 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 238000002600 positron emission tomography Methods 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 230000033764 rhythmic process Effects 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 230000004039 social cognition Effects 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 231100000736 substance abuse Toxicity 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 229910052722 tritium Inorganic materials 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 239000003038 vasopressin antagonist Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
• QMFJIJFIHIDENY-UHFFFAOYSA-N 1-Methyl-1,3-cyclohexadiene Chemical compound CC1=CC=CCC1 QMFJIJFIHIDENY-UHFFFAOYSA-N 0.000 description 1
• YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 description 1
• CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• NXRGLRGWLQLZHJ-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane-2-carboxylic acid;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C(=O)O)CC11CNC1 NXRGLRGWLQLZHJ-UHFFFAOYSA-N 0.000 description 1
• RSVLENUQKOZMAG-UHFFFAOYSA-N 2-(6-methoxypyridin-3-yl)-2,6-diazaspiro[3.3]heptane Chemical compound COC1=CC=C(C=N1)N1CC2(C1)CNC2 RSVLENUQKOZMAG-UHFFFAOYSA-N 0.000 description 1
• FZCQMIRJCGWWCL-UHFFFAOYSA-N 2-amino-5-chlorophenol Chemical compound NC1=CC=C(Cl)C=C1O FZCQMIRJCGWWCL-UHFFFAOYSA-N 0.000 description 1
• BSGJWDYVBDFDFI-UHFFFAOYSA-N 2-benzyl-2,6-diazaspiro[3.3]heptane Chemical compound C=1C=CC=CC=1CN(C1)CC21CNC2 BSGJWDYVBDFDFI-UHFFFAOYSA-N 0.000 description 1
• IFGLECYAEGYLSJ-UHFFFAOYSA-N 2-bromo-3-fluoropyridine Chemical compound FC1=CC=CN=C1Br IFGLECYAEGYLSJ-UHFFFAOYSA-N 0.000 description 1
• UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 1
• ITAJKPNAPXHDDZ-UHFFFAOYSA-N 2-chloro-5-fluoro-4-methylpyrimidine Chemical compound CC1=NC(Cl)=NC=C1F ITAJKPNAPXHDDZ-UHFFFAOYSA-N 0.000 description 1
• UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
• KHWLDKURLKKFNZ-UHFFFAOYSA-N 2-pyrimidin-2-yl-2,6-diazaspiro[3.3]heptane 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C1NCC11CN(C1)c1ncccn1 KHWLDKURLKKFNZ-UHFFFAOYSA-N 0.000 description 1
• NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
• INWUFXPCLZRSBH-UHFFFAOYSA-N 3-chloro-1,2-benzoxazole Chemical compound C1=CC=C2C(Cl)=NOC2=C1 INWUFXPCLZRSBH-UHFFFAOYSA-N 0.000 description 1
• GXBWRBSCBONTKK-UHFFFAOYSA-N 3-chloro-5-methylpyridazine Chemical compound CC1=CN=NC(Cl)=C1 GXBWRBSCBONTKK-UHFFFAOYSA-N 0.000 description 1
• XBOMEOMTVVEEDW-UHFFFAOYSA-N 4,5-difluoro-2-iodoaniline Chemical compound NC1=CC(F)=C(F)C=C1I XBOMEOMTVVEEDW-UHFFFAOYSA-N 0.000 description 1
• FLEJOBRWKBPUOX-UHFFFAOYSA-N 4-chloro-2-iodoaniline Chemical compound NC1=CC=C(Cl)C=C1I FLEJOBRWKBPUOX-UHFFFAOYSA-N 0.000 description 1
• 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
• MICHSUASYRCZFL-UHFFFAOYSA-N 6,7-difluoro-3-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound FC1=C(F)C=C2NC(C)COC2=C1 MICHSUASYRCZFL-UHFFFAOYSA-N 0.000 description 1
• SKJPEOOFMVVZSJ-UHFFFAOYSA-N 6-benzyl-2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptane Chemical compound C(C1=CC=CC=C1)N1CC2(C1)CN(C2)C1=NC=C(C=C1)F SKJPEOOFMVVZSJ-UHFFFAOYSA-N 0.000 description 1
• WOYMBVUWQFWVSA-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1h-quinolin-4-one Chemical compound N1CCC(=O)C2=CC(Cl)=CC=C21 WOYMBVUWQFWVSA-UHFFFAOYSA-N 0.000 description 1
• OASOJRLJBDCVNU-UHFFFAOYSA-N 7-bromoimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C=CN2C=CN=C21 OASOJRLJBDCVNU-UHFFFAOYSA-N 0.000 description 1
• HTTPRAKPCRHHCF-UHFFFAOYSA-N 7-chloro-3-ethyl-2H-1,4-benzoxazine Chemical compound CCC1=NC2=CC=C(Cl)C=C2OC1 HTTPRAKPCRHHCF-UHFFFAOYSA-N 0.000 description 1
• UVWNORIHOSLHIO-UHFFFAOYSA-N 7-fluoro-3-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound FC1=CC=C2NC(C)COC2=C1 UVWNORIHOSLHIO-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 241000349731 Afzelia bipindensis Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 208000009575 Angelman syndrome Diseases 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010003225 Arteriospasm coronary Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• WMKZGQWPXSWVNT-UHFFFAOYSA-N CC(CO)Nc1ccc(Cl)cc1I Chemical compound CC(CO)Nc1ccc(Cl)cc1I WMKZGQWPXSWVNT-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 206010008469 Chest discomfort Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000017164 Chronobiology disease Diseases 0.000 description 1
• 235000021513 Cinchona Nutrition 0.000 description 1
• 241000157855 Cinchona Species 0.000 description 1
• 208000027691 Conduct disease Diseases 0.000 description 1
• 208000003890 Coronary Vasospasm Diseases 0.000 description 1
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 208000012239 Developmental disease Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000573411 Homo sapiens Vasopressin-neurophysin 2-copeptin Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010048533 Hypervigilance Diseases 0.000 description 1
• 201000001916 Hypochondriasis Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010021036 Hyponatraemia Diseases 0.000 description 1
• 206010066151 Hyponatraemic encephalopathy Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 206010027951 Mood swings Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 206010029216 Nervousness Diseases 0.000 description 1
• GMPZPHGHNDMRKL-RZDIXWSQSA-N O([C@H]1CC[C@@H](CC1)C1=NN=C2CN(CC3=CC(Cl)=CC=C3N21)C)C1=CC=CC=N1 Chemical compound O([C@H]1CC[C@@H](CC1)C1=NN=C2CN(CC3=CC(Cl)=CC=C3N21)C)C1=CC=CC=N1 GMPZPHGHNDMRKL-RZDIXWSQSA-N 0.000 description 1
• OAZMVHGXRXAPNW-UHFFFAOYSA-N OC(=O)C(F)(F)F.C1NCC11CN(C1)c1cccnc1 Chemical compound OC(=O)C(F)(F)F.C1NCC11CN(C1)c1cccnc1 OAZMVHGXRXAPNW-UHFFFAOYSA-N 0.000 description 1
• 206010030043 Ocular hypertension Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 101800000989 Oxytocin Proteins 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 206010062519 Poor quality sleep Diseases 0.000 description 1
• 201000009916 Postpartum depression Diseases 0.000 description 1
• 208000005107 Premature Birth Diseases 0.000 description 1
• 206010036590 Premature baby Diseases 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 206010039740 Screaming Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000003028 Stuttering Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
• 206010068932 Terminal insomnia Diseases 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 208000037175 Travel-Related Illness Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 208000028938 Urination disease Diseases 0.000 description 1
• 102100037187 Vasopressin V1a receptor Human genes 0.000 description 1
• 102100037188 Vasopressin V1b receptor Human genes 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 238000012084 abdominal surgery Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 230000009858 acid secretion Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000008856 allosteric binding Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003502 anti-nociceptive effect Effects 0.000 description 1
• 229940124538 antidiuretic agent Drugs 0.000 description 1
• 239000003160 antidiuretic agent Substances 0.000 description 1
• 230000000338 anxiogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000000010 aprotic solvent Substances 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 125000003828 azulenyl group Chemical group 0.000 description 1
• 229940070164 balovaptan Drugs 0.000 description 1
• 108091008698 baroreceptors Proteins 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000009045 body homeostasis Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000003306 cell dissemination Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 230000003280 chronobiological effect Effects 0.000 description 1
• 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 208000027744 congestion Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 201000011634 coronary artery vasospasm Diseases 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000002178 crystalline material Substances 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
• 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
• 230000003001 depressive effect Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000008918 emotional behaviour Effects 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 201000003104 endogenous depression Diseases 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• RJWPDBVOXKGNGW-ZETCQYMHSA-N ethyl (2S)-2-(4-chloro-2-iodoanilino)propanoate Chemical compound ClC1=CC(=C(C=C1)N[C@@H](C)C(=O)OCC)I RJWPDBVOXKGNGW-ZETCQYMHSA-N 0.000 description 1
• 229940116333 ethyl lactate Drugs 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 239000002360 explosive Substances 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000037870 generalized anxiety Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 125000002192 heptalenyl group Chemical group 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000045694 human AVP Human genes 0.000 description 1
• 102000049003 human AVPR1A Human genes 0.000 description 1
• 102000055515 human AVPR1b Human genes 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 125000003427 indacenyl group Chemical group 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000008040 ionic compounds Chemical class 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
• 230000006742 locomotor activity Effects 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000001055 magnesium Nutrition 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000029082 maternal behavior Effects 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 201000003995 melancholia Diseases 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 201000003152 motion sickness Diseases 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000000754 myometrium Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 210000000885 nephron Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000003188 neurobehavioral effect Effects 0.000 description 1
• 230000001722 neurochemical effect Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 208000015706 neuroendocrine disease Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 239000000712 neurohormone Substances 0.000 description 1
• 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
• 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000002997 ophthalmic solution Substances 0.000 description 1
• 229940054534 ophthalmic solution Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
• 229960001723 oxytocin Drugs 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 230000037324 pain perception Effects 0.000 description 1
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
• 208000022821 personality disease Diseases 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000010363 phase shift Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000007867 post-reaction treatment Methods 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 206010036596 premature ejaculation Diseases 0.000 description 1
• 210000001774 pressoreceptor Anatomy 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 239000003368 psychostimulant agent Substances 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000005412 pyrazyl group Chemical group 0.000 description 1
• 125000001725 pyrenyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 210000005227 renal system Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000035941 sexual motivation Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 230000008454 sleep-wake cycle Effects 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 210000001679 solitary nucleus Anatomy 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000012005 synaptopathy Diseases 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 230000001477 vasopressinergic effect Effects 0.000 description 1
• 230000001755 vocal effect Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1